A Phase I/IIa, Dual-cohort, Two-site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma

Trial Profile

A Phase I/IIa, Dual-cohort, Two-site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs MAGE A3 6 specific t cells (Primary) ; NTBI 1301 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 08 Aug 2016 According to an Adaptimmune media release, status changed from active, no longer recruiting to completed.
    • 11 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2021.
    • 07 Jun 2016 Trial design for six studies including this study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top